menu
    • menu
    [{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Wellington Management"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series C Financing","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Deep Track Capital","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Deep Track Capital"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by MBX Biosciences

    Menu

    MBX Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Completes Enrollment in Phase 2 Avail Trial for MBX 2109

                            Details : MBX 2109 (canvuparatide) is a long-acting PTH peptide prodrug which is currently being evaluated for the treatment of patients with hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Positive Phase 1 Results for MBX 1416 in Hypoglycemia

                            Details : MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.

                            Product Name : MBX 1416

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Pricing of Initial Public Offering

                            Details : The proceeds will advance the development of MBX 2109 and MBX 1416, two clinical programs, MBX 4291. MBX 2109 is designed as a potential long-acting hormone replacement therapy for hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Pricing of Initial Public Offering

                            Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial for Hypoparathyroidism

                            Details : MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 08, 2024

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Completes Phase 1 MBX 1416 Study for Post-Bariatric Hypoglycemia

                            Details : MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.

                            Product Name : MBX 1416

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $187.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX Biosciences Closes Upsized IPO, Underwriters Purchase Additional Shares

                            Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $187.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX files for IPO, Seeking Cash to Take Challenger to Ascendis' Yorvipath into Phase 3

                            Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            August 26, 2024

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $63.5 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            MBX Biosciences Raises $63.5M in Series C to Advance Precision Endocrine Peptide™ Platform

                            Details : The net proceeds from the financing will be used to advance the clinical development of the company's lead product, MBX 2109, which is being evaluated for the treatment of hypoparathyroidism.

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            May 08, 2024

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $63.5 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroi...

                            Details : MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism. It was designed with the company’s novel, proprietary Precision Endocrine Peptide™ (PEP™) platform te...

                            Product Name : MBX 2109

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : Canvuparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth